All posts related to "ankylosing spondylitis"

ACR News: New Treatment opportunities in axial spondyloarthritis

Picture of Dr. ElewautGood news for Arthritis Consumer Experts (ACE) members and subscribers who live with a form of ankylosing spondylitis. Within the arthritis research world, the field of ankylosing spondylitis is rapidly progressing, and very exciting new discoveries are being made. At the American College of Rheumatology (ACR) annual meeting, Dr. Dirk Elewaut, Professor of Rheumatology and Immunology and Chair of the Department of Rheumatology at Ghent University Hospital, Belgium, discussed the importance of gut inflammation in spondyloarthritis.

Continue reading

Health Canada approves biosimilar etanercept for RA and AS

Approved stampHealth Canada approves biosimilar etanercept for rheumatoid arthritis and ankylosing spondylitis

What does this mean for patients?  

On August 31, 2016, the biosimilar etanercept (BRENZYS) was approved for the treatment of rheumatoid arthritis and ankylosing spondylitis.

BRENZYS is a subsequent entry biologic (biosimilar) to the Canadian authorized reference product, Enbrel. Both contain the active pharmaceutical ingredient, etanercept. Continue reading

JointHealth™ insight: The latest news on provincial drug formulary

In this issue of JointHealth™ insight, Arthritis Consumer Experts (ACE) maps out the latest news for you about provincial drug formulary listing decisions. It contains information about important changes to provincial drug formularies and what it means for Canadians living with inflammatory arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA).

Map of Canada with highlights of changesManitoba
The following medication has been listed for reimbursement on the provincial drug formulary: Continue reading

JointHealth™ insight – Medications Guide Edition, June 2016

State of Arthritis Medications: Some old, some new, all important

JointHealth Meds Slide for 2016The reliable, quick reference arthritis medications guide you need to assist you and your health care team with your therapy conversations.

The JointHealth™ Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis and osteoarthritis. Medication information for the following diseases is included in this year’s guide: rheumatoid arthritis, ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, vasculitis, osteoarthritis, and osteoporosis.

In this JointHealth™ insight, you will also find:

  • An explanation of the naming changes in the different categories of
    arthritis medications
  • Insight into the patient-physician therapy conversation by Cheryl Koehn, Founder and President of Arthritis Consumer Experts
  • Updated disease information for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, and lupus
  • The latest research on methotrexate and the consumption of alcoholic beverages

 

Let BC PharmaCare hear “Your Voice” on secukinumab

Stickman with megaphone calling for patient inputBC PharmaCare is looking for your input on secukinumab for the treatment of ankylosing spondylitis and psoriatic arthritis

Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about secukinumab for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

You can give input if you are a B.C. resident and have AS or PsA, a caregiver to someone with AS or PsA, or if your group represents people who live with AS or PsA.

The submission deadline is midnight on July 21, 2016. Patients and caregivers may give their input directly through the links below.
Continue reading

The lastest provincial listings, at your fingertips

Map of Canada

(Please click on the map for more information about the provincial drug formulary updates.)

The latest provincial listings, at your fingertips

Good news for people living with autoimmune arthritis in Canada!

Arthritis Consumer Experts (ACE) maps out the latest news for you: Read about the important changes to provincial drug formularies and what it means for Canadians living with autoimmune arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Continue reading

Call for patient input on SEB etanercept for RA and AS

Stickman with megaphone calling for patient input

Call for patient input on SEB etanercept for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Do you have RA or AS or care for someone who does? We need your valuable input.

Health Canada defines subsequent entry biologics (SEBs) as biologic medicines that are similar to, and would enter the market after an approved innovator biologic (such as Enbrel®).

Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. SEBs are not identical to their innovator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, SEBs may have unique efficacy, immunogenicity, and safety profiles that are different from their innovator products.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for SEB etanercept for the treatment of rheumatoid arthritis or ankylosing spondylitis. The innovator biologic, or reference product, is etanercept (Enbrel®). Continue reading

Canada’s first measures of performance in treating inflammatory arthritis

Performance meterA team of researchers has developed Canada’s first set of systematic measures for tracking how well or poorly health systems are doing in providing services to people who have inflammatory arthritis (IA), a potentially crippling disease that is on the rise in Canada.

The researchers developed six key measures for gauging access to specialist care and initiation of treatment for people with IA, a disease grouping that includes rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. The work is described in March issue of The Journal of Rheumatology.

People who receive early diagnosis and start of treatment have a better chance of responding well and avoiding permanent joint damage from rheumatoid arthritis (RA), the most common form of IA. There is a growing body of evidence that early detection and treatment are also crucial to good outcomes for people who have other types of IA. Continue reading

Register now for the 2016 Spondyloarthritis Patient Forum

This forum will help patients with ankylosing spondylitis and psoriatic arthritis and their family. Register now for free!
Forum bannerThe Spondyloarthritis Research Consortium of Canada and the Canadian Spondylitis Association, in collaboration with The Arthritis Society, would like to invite you to register for free to the 2016 Spondyloarthritis Patient Forum. The forum aims to help patients living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) and their family. Light refreshments will be provided.

Here are the event details:

Date: Saturday, April 30, 2016
Location: Sheraton Vancouver Wall Centre, Junior Ballroom CD
1088 Burrard Street, Vancouver
Time: 3:30pm-7:00pm
Cost: Free

Please note pre-registration is required. Seats are limited. You can register: Continue reading

Demande de rétroaction de patients sur le secukinumab (Cosentyx®) dans le traitement de la spondylarthrite ankylosante et de l’arthrite psoriasique

Megaphone GraphicSouffrez-vous de spondylarthrite ankylosante ou d’arthrite psoriasique ou prodiguez-vous des soins à quelqu’un qui en souffre ? Vos commentaires seraient précieux.

Le Programme commun d’évaluation des médicaments (PCEM) invite actuellement les patients et leurs fournisseurs de soins à faire parvenir aux organismes représentant les patients leurs suggestions et commentaires sur la présentation par le fabricant du secukinumab (Cosentyx®) dans le traitement de la spondylarthrite ankylosante et de l’arthrite psoriasique. Le secukinumab est un anticorps monoclonal entièrement humain qui cible l’action de l’interleukine 17A (IL-17A), une protéine au cœur du développement des maladies inflammatoires. Le secukinumab est administré par injection.

Faisant partie de l’Agence canadienne des médicaments et des technologies de la santé, le PCEM examine avec objectivité et rigueur l’efficacité et la rentabilité des médicaments et fournit des recommandations aux régimes d’assurance-médicaments publics du Canada (à l’exception du Québec) quant à leur inscription sur la liste des médicaments assurés.

Afin de l’aider dans son processus de recommandation, le PCEM accepte la rétroaction de groupe de patients comme le comité ACE (Arthritis Consumer Experts). Nous souhaitons recueillir les commentaires de nos membres, nos abonnés et les membres de leur famille atteints de spondylarthrite ankylosante ou d’arthrite psoriasique. Les fournisseurs de soins sont également invités à nous faire parvenir leurs commentaires.

Nous désirons communiquer votre point de vue au PCEM. Continue reading